Quisovalimab

DB16482InvestigationalProtein Based Therapies

Quisovalimab: Overview.

Mechanism: CERC-002 is an anti-LIGHT monoclonal antibody associated with cytokine storm and the induction of Acute Respiratory Distress Syndrome (ARDS).
Curator reviewed
Also known as: Immunoglobulin G4 [230-proline,237-glutamic acid], anti-(human tumor necrosis factor superfamily protein TNFSF14) (human-Mus musculus monoclonal SAR252067 γ4-chain), disulfide with human-Mus musculus monoclonal SAR252067 .kappa.-chain, dimer
Code names: AEVI-002 · AVTX-002 · CERC-002 · MDGN-002 · SAR-252067

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Quisovalimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.